Serrétia is the world's strongest Serrapeptase with a minimum activity of 250,000 SPU's per dose.

Originally discovered in the intestine of silkworms, the proteolytic enzyme Serrapeptase is harnessed by Arthur Andrew Medical through the isolation of the microorganism, Serratia E-15. Serrapeptase’s inherent ability to digest dead tissue enables the enzyme to successfully aid in supporting normal scar tissue, normal blood clotting, and allows for more fluid and natural blood flow throughout the body.*

Serrétia has a variety of different benefits that may help with the following:

• Sport injuries*
• Promote healthy sinus activity*
• Promote free joint mobility*
• Muscle tears and pulls*
• Surgical recovery*
• Normal fluid retention such as swelling*

Serrétia’s Use for Sports Injuries

NSAID’s do an effective job of masking the pain and inflammation of an injury, however merely masking the aforementioned symptoms, may prolong recovery.* The use of systemic enzymes such as Serrétia, may provide an additional choice for supporting normal recovery.* Serrétia works by digesting any dead tissue that may accumulate as a result of an injury, which then allows normal fluid retention to take place, thereby aiding in a normal inflammatory response, while assisting one’s ability to heal.*

Studies on Sport Injuries:

In Europe the overall use of systemic enzymes has been far more widespread than in the United States. In Germany in particular, systemic enzymes have been actively used for decades and are even used by the German National Hockey to support physical health.*

German Dr. M. W. Kleine and his team at the Sports Medicine Investigation Center in Grumwald, Germany, decided to look at 100 athletes in order to determine the ‘effectiveness of proteolytic enzymes’. Dr. Kleine took each subject and removed two cubic cm of blood from their anticubital vein. By reinserting the blood under the skin on each subject’s right forearm, Dr. Kleine and his team were able to reproduce a hematoma (blood clot). 50 of the subjects were then given placebo pills, while the other 50 subjects were given proteolytic enzymes; each subject taking one pill three times a day. The results speak for themselves: 35 or 70% of the 50 subjects that had been treated with enzymes reported considerably less discomfort, normal inflammation, a shorter lasting amount of discomfort on pressure and had the hematoma disappear in a shorter amount of time than their placebo counterparts.*